Alterations in Gut Microbiome Composition and Function in Irritable Bowel Syndrome and Increased Probiotic Abundance with Daily SupplementationOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study examined the gut microbiome composition and function of people with irritable bowel syndrome (IBS) compared to healthy controls, using metagenomic sequencing of stool samples. The researchers aimed to identify microbial features that distinguish IBS and its subtypes from non-IBS individuals. They also tested whether a daily synbiotic supplementation intervention could shift the abundance of IBS-associated microbial features over time.
Who was studied?
The study analyzed stool samples from 490 individuals with IBS, spanning all dominant IBS subtypes, and 122 individuals without IBS as controls. A subset of 134 IBS participants was followed longitudinally while receiving daily synbiotic supplementation, with the supplement composition varying between participants. This represents a comparatively large cohort for microbiome research on IBS symptom heterogeneity.
What were the most important findings?
IBS participants had significantly lower alpha diversity, an enrichment in Gram-negative bacteria, and reduced pathways for short-chain fatty acid and vitamin synthesis compared to controls. Shigella species were significantly associated with IBS, while Eubacterium rectale and Faecalibacterium prausnitzii, both associated with anti-inflammatory, butyrate-related commensal activity, were associated with healthy controls instead. Random forest analysis identified microbial features unique to and shared across the different IBS subtypes. Among the 134 subjects followed over time, daily synbiotic supplementation did not change alpha diversity but did increase probiotic abundance and shift other microbial features.
What are the greatest implications of this study?
The findings support a role for specific microbial imbalances, including depletion of beneficial commensals like Faecalibacterium prausnitzii and Eubacterium rectale and reduced short-chain fatty acid pathways, in distinguishing IBS from healthy states. The identification of subtype-specific and shared microbial features could help inform more targeted diagnostic or treatment approaches for IBS. However, since synbiotic supplementation increased probiotic abundance without restoring overall diversity, the authors note that further work is needed to determine whether these microbiome changes translate into actual improvement of IBS symptoms.